AstraZeneca tired of life? Leaves London and reorganizes global R&D
This article was originally published in Scrip
AstraZeneca's new CEO Pascal Soriot has wasted little time in putting his stamp on the troubled company since joining six months ago. Today saw the firm announcing sweeping changes to its R&D operations around the globe. This comes just three days before the unveiling of Mr Soriot's strategy review conclusions at an investor day in New York.
You may also be interested in...
As head of AstraZeneca's global research and early development arms Menelas Pangalos has, in the space of eight years, boosted AstraZeneca's pipeline productivity from below industry average to one of the best, at a fraction of the cost. He talked to Scrip about how he effected this transformation using his "5R" framework, and what he needs to do next.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.